http://www.advfn.com/nasdaq/rss.asp?symbol=GILD Gilead Sciences Company Newsfeed en Thu, 23 May 2013 08:32:21 EDT Thu, 23 May 2013 08:32:21 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57702530&headline=royalty-pharma-lowers-acceptance-threshold-for-elan-offer http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57702530&headline=royalty-pharma-lowers-acceptance-threshold-for-elan-offer <div class='newsbody'><p> By Jessica Hodgson </p> <p> LONDON--Royalty Pharma AG, the New York-based pharmaceutical investor bidding around $6.4 billion in cash for drugmaker Elan Corp. (ELN) Thursday said it was lowering the threshold for shareholder acceptance for its offer to 50% plus one share, from... Thu, 23 May 2013 08:32:21 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57684457&headline=u-s-hot-stock-futures-hot-stocks-to-watch http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57684457&headline=u-s-hot-stock-futures-hot-stocks-to-watch <div class='newsbody'><p> Among the companies with shares expected to actively trade in Wednesday's session are Saks Inc. (SKS), Zale Corp. (ZLC) and Multiband Corp. (MBND). </p> <p> Luxury retailer Saks has hired Goldman Sachs Group Inc. (GS) to explore strategic alternatives, including a possible sale... Wed, 22 May 2013 09:16:40 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57674301&headline=gilead-hepatitis-c-drug-gets-accelerated-review http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57674301&headline=gilead-hepatitis-c-drug-gets-accelerated-review <div class='newsbody'><p> Gilead Sciences Inc. (GILD) said the marketing authorization application for its new hepatitis C drug has been validated by the European Medicines Agency and granted accelerated assessment. </p> <p> Gilead is also seeking U.S. Food and Drug Administration approval for the once-daily... Tue, 21 May 2013 18:00:04 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57674203&headline=gilead-hepatitis-c-drug-sofosbuvir-granted-accelerated-review http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57674203&headline=gilead-hepatitis-c-drug-sofosbuvir-granted-accelerated-review <div class='newsbody'><pre> By Debbie Cai </pre> <p> Gilead Sciences Inc. (GILD) said the marketing authorization application for its new hepatitis C drug has been validated by the European Medicines Agency and granted accelerated assessment. </p> <p> Gilead is also seeking U.S. Food and Drug Administration... Tue, 21 May 2013 17:44:39 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57417794&headline=gilead-sciences-1st-quarter-profit-jumps-63 http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57417794&headline=gilead-sciences-1st-quarter-profit-jumps-63 <div class='newsbody'><pre> By Mia Lamar </pre> <p> Gilead Sciences Inc.'s (GILD) first-quarter earnings rose 63% as the biopharmaceutical company reported increased sales for the newer additions to its HIV drug franchise. </p> <p> Gilead's HIV treatment Stribild, which was launched in late August, contributed... Thu, 02 May 2013 16:59:50 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57384935&headline=vertex-pharmaceuticals-swings-to-1st-quarter-loss-on-write-down http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57384935&headline=vertex-pharmaceuticals-swings-to-1st-quarter-loss-on-write-down <div class='newsbody'><pre> By Debbie Cai </pre> <p> Vertex Pharmaceuticals Inc. (VRTX) swung to a first-quarter loss on a write-down tied to its hepatitis C program, as sales of Incivek also slid. </p> <p> The pharmaceutical company has now reported four straight quarters of losses amid slumping sales... Tue, 30 Apr 2013 17:02:11 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57364793&headline=regeneron-pharmaceuticals-co-founder-receives-81-55-million http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57364793&headline=regeneron-pharmaceuticals-co-founder-receives-81-55-million <div class='newsbody'><pre> By Joseph Walker </pre> <p> Regeneron Pharmaceuticals Inc.'s (REGN) stock price tripled last year, and the compensation of co-founder and Chief Executive Leonard Schleifer nearly did, too. </p> <p> Mr. Schleifer made $30.04 million in 2012, according to filings with the Securities... Mon, 29 Apr 2013 15:04:16 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57359318&headline=gilead-says-fda-rejects-new-drug-applications-for-elvitegravir http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57359318&headline=gilead-says-fda-rejects-new-drug-applications-for-elvitegravir <div class='newsbody'><pre> By Melodie Warner </pre> <p> Gilead Sciences Inc. (GILD) said the U.S. Food and Drug Administration rejected its new drug applications for the use of elvitegravir and cobicistat as part of HIV treatment regimens. </p> <p> The biopharmaceutical company said the FDA's complete... Mon, 29 Apr 2013 09:25:04 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57339793&headline=as-biotechnology-stocks-soar-bubble-talk-percolates http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57339793&headline=as-biotechnology-stocks-soar-bubble-talk-percolates <div class='newsbody'><pre> By Joseph Walker </pre> <p> Biotechnology stocks are quite healthy right now, but some think they are due for a cold. </p> <p> The sector is on a run not seen since the go-go days of the late 1990s, bolstered by a string of clinical and regulatory successes that analysts say... Fri, 26 Apr 2013 09:42:31 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57283367&headline=bristol-says-results-of-hepatitis-c-drug-trial-are-positive http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=57283367&headline=bristol-says-results-of-hepatitis-c-drug-trial-are-positive <div class='newsbody'><pre> By Peter Loftus </pre> <p> An experimental drug cocktail from Bristol-Myers Squibb Co. (BMY) cleared the hepatitis C virus in most patients in a mid-stage clinical trial--results that could keep the company in the race to develop the next generation of treatments for the liver... Tue, 23 Apr 2013 06:30:00 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56885224&headline=idenix-loses-1st-stage-of-drug-compounds-patent-case http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56885224&headline=idenix-loses-1st-stage-of-drug-compounds-patent-case <div class='newsbody'><pre> By Debbie Cai </pre> <p> The U.S. Patent and Trademark Office has decided against Idenix Pharmaceuticals Inc. (IDIX) in the first phase of a two-stage interference process regarding the biopharmaceutical company's patent applications for certain compounds useful in the treatment... Fri, 22 Mar 2013 17:40:51 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56884316&headline=gentium-gets-negative-opinion-from-chmp-biogen-others-get-positive http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56884316&headline=gentium-gets-negative-opinion-from-chmp-biogen-others-get-positive <div class='newsbody'><pre> By Saabira Chaudhuri </pre> <p> Gentium SpA (GENT) said the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion, recommending the refusal of marketing authorization for its treatment for hepatic veno-occlusive disease. </p> <p>... Fri, 22 Mar 2013 09:33:25 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56634693&headline=pfizer-stops-developing-hepatitis-c-drug-cites-strategic-review http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56634693&headline=pfizer-stops-developing-hepatitis-c-drug-cites-strategic-review <div class='newsbody'><pre> By Peter Loftus </pre> <p> Pfizer Inc. (PFE) has stopped development of an experimental hepatitis C drug, bowing out of a hotly contested industry race to introduce the next generation of treatments for the infectious liver disease. </p> <p> The New York-based drug giant decided... Fri, 08 Mar 2013 12:27:09 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56552347&headline=elan-sweetens-shareholder-deal http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56552347&headline=elan-sweetens-shareholder-deal <div class='newsbody'><pre> By Jessica Hodgson </pre> <p> LONDON--Irish biotech company Elan Corp. PLC (ELN) Monday said it would sweeten an incentive to shareholders to remain invested in the company but provided little in the way of detail about acquisition targets, casting further doubt over its future... Mon, 04 Mar 2013 08:20:54 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56441013&headline=royalty-pharma-offers-6-55-billion-for-elan http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56441013&headline=royalty-pharma-offers-6-55-billion-for-elan <div class='newsbody'><p> LONDON--Pharmaceutical investor Royalty Pharma LLC Monday disclosed it had approached Elan Corp. (ELN) last week about a takeover and made a $6.55 billion offer after talks with the company, two days before the Irish drug maker outlined its investment plans after the sale of... Mon, 25 Feb 2013 08:10:06 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56382501&headline=gilead-teva-reach-preliminary-pact-in-viread-patent-dispute http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56382501&headline=gilead-teva-reach-preliminary-pact-in-viread-patent-dispute <div class='newsbody'><pre> By Tess Stynes </pre> <p> Gilead Sciences Inc. (GILD) said it reached a preliminary settlement in long-running legal battle with Teva Pharmaceutical Industries Ltd. (TEVA) over patents related to the U.S. biopharmaceutical company's Viread drug. </p> <p> The preliminary accord... Wed, 20 Feb 2013 09:36:10 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56361876&headline=gilead-sees-positive-results-from-late-stage-hepatitis-c-treatment http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56361876&headline=gilead-sees-positive-results-from-late-stage-hepatitis-c-treatment <div class='newsbody'><pre> By Saabira Chaudhuri </pre> <p> Gilead Sciences Inc. (GILD) said results from the fourth late-stage study evaluating its hepatitis C treatment were positive. </p> <p> The study evaluates 12- and 16-week courses of therapy with Gilead's once-daily nucleotide sofosbuvir plus... Tue, 19 Feb 2013 09:16:05 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56335206&headline=gilead-recalls-lot-of-vistide-due-to-particulate-matter http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56335206&headline=gilead-recalls-lot-of-vistide-due-to-particulate-matter <div class='newsbody'><pre> By Nathalie Tadena </pre> <p> Gilead Sciences Inc. (GILD) is voluntarily recalling a lot of its Vistide antiviral drug due to the presence of particulate matter found in some of the lot's vials. </p> <p> The biopharmaceutical company is recalling Vistide B120217A, which has... Fri, 15 Feb 2013 19:37:08 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56150147&headline=correction-to-u-s-hot-stock-futures-table http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56150147&headline=correction-to-u-s-hot-stock-futures-table <div class='newsbody'><p> "U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH," at 6 a.m. EST, misstated the stock price for Idenix Pharmaceuticals Inc. (IDIX). Shares closed Monday at $4.73 and declined after hours. </p> <p> Subscribe to WSJ: http://online.wsj.com?mod=djnwires </p> <pre> </pre> </div> Tue, 05 Feb 2013 10:16:52 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56136812&headline=gilead-4th-quarter-profit-rose-15-on-strong-revenue-growth-led http://www.advfn.com/nasdaq/StockNews.asp?stocknews=GILD&article=56136812&headline=gilead-4th-quarter-profit-rose-15-on-strong-revenue-growth-led <div class='newsbody'><pre> By Tess Stynes </pre> <p> Gilead Sciences Inc.'s (GILD) fourth-quarter earnings rose 15% as the biopharmaceutical company reported double-digit revenue growth, mostly driven by strong sales of its HIV drugs. </p> <p> Shares were up 2.3% % at $40.49 in recent after-hours trading... Mon, 04 Feb 2013 16:57:06 EST